Back to top
more

Gilead Sciences (GILD)

(Delayed Data from NSDQ)

$88.82 USD

88.82
5,811,906

+0.53 (0.60%)

Updated Oct 31, 2024 04:00 PM ET

After-Market: $88.74 -0.08 (-0.09%) 7:26 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value B Growth C Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 31% (79 out of 251)

Industry: Medical - Biomedical and Genetics

Better trading starts here.

Zacks News

5 Best Biotech Stocks to Buy In October

Successful drug trials at several biopharmas and FDA approvals make biotech companies a strong investment choice in October

    3 Biotech Stocks With Rising Estimates in the Past Month

    The biotech industry is performing reasonably well. Hence, it is a good idea to select stocks from the sector witnessing positive estimate revisions.

      Ryan McQueeney headshot

      Guide to CRISPR Stocks & Latest Apple, Fed, GDP News | Free Lunch

      Ryan McQueeney highlights the Fed's latest rate hike sentiment and new revisions to GDP growth estimates. He also recaps Bed Bath & Beyond's earnings results and touches on analyst research related to Apple. Later, he is joined by Zacks' biotech guru, Kevin Cook, to chat about CRISPR stocks and how to invest in the developing science.

        Alexion (ALXN) to Acquire Biotech Syntimmune for $1.2 Billion

        Alexion (ALXN) will acquire clinical-stage biotech company, Syntimmune for $1.2 billion to augment its rare disease pipeline.

          Gilead Sciences (GILD) Gains As Market Dips: What You Should Know

          In the latest trading session, Gilead Sciences (GILD) closed at $75.65, marking a +0.81% move from the previous day.

            Biotech Stock Roundup: ALXN Soliris Successful, Respite For Sarepta, AMRN Soars

            Data read-outs by quite a few companies grabbed headlines in the biotech sector this week.

              Gilead (GILD) to Launch Generics for Leading HCV Treatments

              Given the persistent decline in HCV sales, Gilead (GILD) plans to launch authorized generic versions of its leading hepatitis C virus (HCV) treatments, Epclusa and Harvoni.

                Exelixis, Ipsen Receive Positive CHMP Opinion for Cabometyx

                Exelixis, Inc. (EXEL) and partner Ipsen get a positive opinion from the CHMP for Cabometyx tablets as a monotherapy for the second-line treatment of hepatocellular carcinoma in adults.

                  CHMP Reconfirms Negative Opinion for Sarepta's Exondys

                  The CHMP re-confirmed the negative opinion for Sarepta's (SRPT) Exondys, which is developed to treat individuals who have a specific type of Duchenne muscular dystrophy.

                    Rubius (RUBY) in Focus: Stock Moves 8.7% Higher

                    Rubius (RUBY) saw a big move last session, as its shares jumped nearly 9% on the day, amid huge volumes.

                      FDA Confirms Positive Safety Profile of Acadia's Nuplazid

                      Acadia's shares soar more than 20% as the FDA issues a statement reaffirming the positive benefit-risk profile of Nuplazid for patients with Parkinson's disease psychosis.

                        Exelixis' Partner Ipsen Gets Approval for Cabometyx in Canada

                        Exelixis (EXEL) and partner Ipsen Biopharmaceuticals Canada gain approval for Cabometyx from Health Canada for the treatment of advanced renal cell carcinoma in adult patients.

                          Ultragenyx's Shares Surge More Than 80% in the Year So Far

                          Ultragenyx's (RARE) share price has increased by about 85.2% year to date based on some positive developments for the product candidates of the company.

                            Molecular Templates Surges 50%, Inks Cancer Deal With Takeda

                            Molecular Templates (MTEM) signs a collaborative contract with Japan's Takeda for jointly developing CD38-targeted engineered toxin antibodies to treat multiple myeloma. The stock soars past 50%.

                              The Zacks Analyst Blog Highlights: Regeneron Pharmaceuticals, Celgene, Sanofi and Gilead Sciences

                              The Zacks Analyst Blog Highlights: Regeneron Pharmaceuticals, Celgene, Sanofi and Gilead Sciences

                                Gilead Sciences (GILD) Outpaces Stock Market Gains: What You Should Know

                                In the latest trading session, Gilead Sciences (GILD) closed at $73.88, marking a +0.31% move from the previous day.

                                  Biotech Stock Roundup: CELG, REGN Present Data, VKTX Soars on Drug's Success

                                  Pipeline updates and data read-outs at the 27th European Academy of Dermatology and Venereology (EADV) Congress in France comprise some of the key developments in the biotech sector this week.

                                    Viking Therapeutics Liver Candidate Passes Test, Shares Soar

                                    Viking Therapeutics (VKTX) pipeline candidate, VK2809, achieves statistically significant reduction in liver fat content and bad cholesterol levels in a phase II study, evaluated for NAFLD.

                                      Dr. Reddy's (RDY) Presence in Generics Market Remains Strong

                                      Dr. Reddy's has a strong hold in the generics market. New product launches, especially complex generics, are likely to drive the generics business at regular intervals.

                                        Is Gilead (GILD) a Suitable Stock for Value Investors Now?

                                        Let's see if Gilead Sciences, Inc. (GILD) stock is a good choice for value-oriented investors right now, or if investors subscribing to this methodology should look elsewhere for top picks.

                                          Theravance, Mylan Report Positive Data on COPD Drug Yupelri

                                          Theravance (TBPH) and partner Mylan post positive data from a late-stage program on COPD Drug, Yupelri.

                                            Agenus Receives Milestone Payment of $5 Million from Incyte

                                            Agenus (AGEN) receives a milestone payment of $5 million from Incyte on the initiation of a phase I study of INCAGN2385.

                                              Should Value Investors Pick Gilead Sciences (GILD) Stock?

                                              Is Gilead Sciences (GILD) a great pick from the value investor's perspective right now? Read on to know more.

                                                Unity (UBX) Catches Eye: Stock Jumps 8.8%

                                                Unity (UBX) saw a big move last session, as its shares jumped nearly 9% on the day, amid huge volumes.

                                                  Gilead Inks Gene Editing Collaboration Deal for HBV Infection

                                                  Gilead (GILD) enters into a strategic collaboration with Precision BioSciences for developing therapies aimed at eliminating hepatitis B virus by using the latter's gene editing platform ARCUS.